Results 201 to 210 of about 58,392 (301)

Development of a Novel Engineered Antibody Format for PSMA-Targeted Radionuclide Therapy. [PDF]

Mol Pharm
Fletcher NL, Houston ZH, Chandler PG, Yan E, Holgate R, Wheatcroft M, Thurecht KJ.   +6 more
europepmc   +1 more source

Targeted radionuclide therapy frontiers in theranostics

, 2017
Francesca Gallivanone
openalex   +2 more sources

Clinical Experience with Targeted Alpha-Emitter Peptide Receptor Radionuclide Therapy (α-PRRT) for Somatostatin Receptor-Positive Neuroendocrine Tumors. [PDF]

Pharmaceuticals (Basel)
Leupe H, Cauwenbergh M, Cleeren F, Dekervel J, Verslype C, Deroose CM.   +5 more
europepmc   +1 more source

Tumor sink effect on melanin-ligand [¹³¹I]ICF01012 in melanoma and its implications for targeted radionuclide therapy. [PDF]

EJNMMI Res
Jouberton E, Besse S, Billoux T, Auzeloux P, Schmitt S, Chezal JM, Sas N, Noirault L, Auriol M, Levesque S, Delmas M, Chaussin B, Chautard E, Miot-Noirault E, Rouanet J, Cachin F.   +15 more
europepmc   +1 more source

On the reduction of imaging time-points for dosimetry in radionuclide therapy. [PDF]

EJNMMI Phys
Gustafsson J, Taprogge J.
europepmc   +1 more source

68Ga-DOTA-NOC PET and Peptide Receptor Radionuclide Therapy in Management of Bilateral Ovarian Metastases from Gastrointestinal Carcinoid [PDF]

, 2012
Sahil Singla, S. Gupta, R Reddy, Prashant Durgapal, Chandrasekhar Bal   +4 more
openalex   +1 more source

Recommendations for reporting preclinical radiobiological studies in targeted radionuclide therapy. [PDF]

Eur J Nucl Med Mol Imaging
Mendes F, Terry SYA, Spiegelberg D, Cornelissen B, Bolcaen J, Nonnekens J, European Working group of Radiobiology of Molecular Radionuclide Therapy.   +6 more
europepmc   +1 more source

Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023 [PDF]

Gianpaolo di Santo, Giulia Santo, Anna Sviridenko, Irene Virgolini   +3 more
openalex   +1 more source

In This Issue

Cancer Science, Volume 116, Issue 12, Page 3225-3227, December 2025.
wiley   +1 more source

IL-33 as a Marker of Poor Early Response in Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy. [PDF]

Int J Mol Sci
Vuleta Nedic K, Gajovic N, Jovanovic I, Jurisevic M, Jovanovic M, Jakovljević S, Popovic B, Djordjevic J, Ignjatovic V, Vukomanovic V.   +9 more
europepmc   +1 more source